Assessing measurement invariance in the EORTC QLQ-C30.
Measurement invariance
Medical oncology
Palliative care
Patient-reported outcomes
Quality of life
Validation studies
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
24
07
2021
pubmed:
31
7
2021
medline:
17
3
2022
entrez:
30
7
2021
Statut:
ppublish
Résumé
We aimed to investigate measurement invariance (MI) in the European Organisation for research and treatment of cancer quality of life questionnaire core 30 (EORTC QLQ-C30) in a heterogeneous sample of patients with cancer. Data from 12 studies within the PROFILES registry were used for secondary analyses (n = 7007). We tested MI by successive restrictions on thresholds, loadings, and intercepts across subgroups based on primary cancer sites, age, sex, time since diagnosis, and life stage, using multigroup confirmatory factor analysis (MGCFA) for ordered categorical measures. We also evaluated the impact of potentially miss-specified parameter equality across groups on latent factor means by releasing threshold and loading equality constraints for each item at a time. Results showed that the highest level of MI (invariance of thresholds, loadings, and intercepts) was found across groups based on time since diagnosis and life stage and to a lesser extent across groups based on sex, age, and primary tumor site. On item level, however, changes in the item's associated factor means were relatively small and in most cases canceled each other out to some extent. Given only a few instances of non-invariance in our study, there is reason to be confident that valid conclusions can be drawn from between-group comparisons of QLQ-C30 latent means as operationalized in our study. Nonetheless, further research into MI between other subgroups for the QLQ-C30 (i.e., treatment effects and ethnicity) is warranted. We stress the importance of including MI evaluations in the development and validation of measurement instruments.
Identifiants
pubmed: 34327634
doi: 10.1007/s11136-021-02961-8
pii: 10.1007/s11136-021-02961-8
pmc: PMC8921013
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
889-901Informations de copyright
© 2021. The Author(s).
Références
Qual Life Res. 2007 Feb;16(1):115-29
pubmed: 17109190
Qual Life Res. 2018 Apr;27(4):999-1014
pubmed: 29350345
Qual Life Res. 2009 Apr;18(3):381-8
pubmed: 19247808
Qual Life Res. 2012 Dec;21(10):1745-53
pubmed: 22193882
Acta Oncol. 2016 Jul;55(7):814-20
pubmed: 26882096
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Health Qual Life Outcomes. 2010 Jul 16;8:69
pubmed: 20637086
J Pain Symptom Manage. 2015 Mar;49(3):611-24
pubmed: 25135657
Qual Life Res. 2018 Aug;27(8):1937-1955
pubmed: 29427216
Eur J Cancer. 2011 Sep;47(14):2188-94
pubmed: 21621408
Educ Psychol Meas. 2016 Feb;76(1):114-140
pubmed: 29795859
Eur J Cancer. 2019 Nov;121:55-63
pubmed: 31561134
Arthritis Rheum. 2003 Apr 15;49(2):156-63
pubmed: 12687505
Front Psychol. 2019 Oct 08;10:2147
pubmed: 31649573
Health Qual Life Outcomes. 2018 Jun 04;16(1):114
pubmed: 29866185
Psychometrika. 2016 Dec;81(4):1014-1045
pubmed: 27402166
Qual Life Res. 2015 Jan;24(1):125-33
pubmed: 25193618
Psychol Assess. 2002 Dec;14(4):439-50
pubmed: 12501569
Qual Life Res. 2006 Aug;15(6):1103-15; discussion 1117-20
pubmed: 16900290